Ceribell, Inc. (CBLL)
NASDAQ (NGS) NASDAQ (NGS) Primary 
CeriBell Expands EEG Platform Beyond Seizures With Delirium, Pediatric Push
CeriBell NASDAQ: CBLL outlined its plans to expand its brainwave-monitoring platform beyond seizure detection, pointing to new products for delirium, pediatric patients and eventually stroke as it continues to build its hospital customer base.
CeriBell, Inc. (CBLL) Q2 2026 Earnings Call Transcript
CeriBell, Inc. (CBLL) Q2 2026 Earnings Call Transcript
Here's What Key Metrics Tell Us About CeriBell, Inc. (CBLL) Q2 Earnings
Although the revenue and EPS for CeriBell, Inc. (CBLL) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
CeriBell, Inc. (CBLL) Reports Q2 Loss, Tops Revenue Estimates
CeriBell, Inc. (CBLL) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to a loss of $0.38 per share a year ago.
CeriBell Q2 Earnings Call Highlights
CeriBell NASDAQ: CBLL reported second-quarter 2026 revenue growth of 33% as increased utilization at existing hospital accounts and continued customer additions supported results. The company also raised its full-year revenue outlook and outlined plans to commercially launch its delirium-monitoring solution later this year.
CeriBell Sees ‘Early Innings' Growth as Hospital Accounts and Usage Hit Records
CeriBell NASDAQ: CBLL executives said the company's first-quarter results reflected continued momentum in both new account additions and increased usage among existing hospital customers, while outlining early progress in new clinical areas including neonatal seizure monitoring and delirium.
CeriBell, Inc. (CBLL) Q1 2026 Earnings Call Transcript
CeriBell, Inc. (CBLL) Q1 2026 Earnings Call Transcript
CeriBell Q1 Earnings Call Highlights
CeriBell NASDAQ: CBLL reported first-quarter revenue growth of 29% and raised its full-year outlook, as management cited higher usage of its seizure monitoring system and the company's strongest quarter of net new hospital additions since becoming public.
CeriBell, Inc. (CBLL) Reports Q1 Loss, Beats Revenue Estimates
CeriBell, Inc. (CBLL) came out with a quarterly loss of $0.52 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to a loss of $0.36 per share a year ago.
CeriBell, Inc. (CBLL) Reports Q4 Loss, Beats Revenue Estimates
CeriBell, Inc. (CBLL) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to a loss of $0.4 per share a year ago.
CBLL Gets FDA Consent for One-of-a-Kind Delirium Monitoring Solution
CeriBell gains FDA clearance for its continuous delirium monitoring solution, boosting its AI-driven EEG platform and expanding its role in critical care.
CeriBell, Inc. (CBLL) Q3 2025 Earnings Call Transcript
CeriBell, Inc. ( CBLL ) Q3 2025 Earnings Call November 4, 2025 4:30 PM EST Company Participants Xingjuan Chao - Co-Founder, President, CEO & Director Scott Blumberg - Chief Financial Officer Conference Call Participants Travis Steed - BofA Securities, Research Division Robert Marcus - JPMorgan Chase & Co, Research Division Brandon Vazquez - William Blair & Company L.L.C., Research Division Joshua Jennings - TD Cowen, Research Division William Plovanic - Canaccord Genuity Corp., Research Division Jeffrey Cohen - Ladenburg Thalmann & Co. Inc., Research Division Presentation Operator Good afternoon, and thank you all for participating in today's call.
